Senseonics SENS recently announced the full availability of its long-term, implantable Continuous Glucose Monitoring (CGM) ...

The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage ...

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...

Senseonics Holdings (SENS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...

The stock has been volatile over the past two years. The company’s Eversense continuous glucose monitoring system has a premarket approval supplement application before the FDA. The company is growing ...

Senseonics (SENS) Holdings has entered into a definitive agreement for the purchase and sale of 45,714,286 shares of its common stock at an offering price of $0.35 per share of common stock in a ...

Detailed price information for Senseonics Holdings Inc (SENS-Q) from The Globe and Mail including charting and trades.